Home ProductsPharmaceutical Raw Materials

Anastrozole Arimidex Anti Estrogen Steroids ISO9001 CAS 120511-73-1

China RawsGear Manufacturer certification
China RawsGear Manufacturer certification
Customer Reviews
Good. I received my 500 kg lidocaine package in the UK within 12 days. Their European customs clearance team is powerful.This is what I want

—— Liam Sneddon — UK

Their steroid powder and tetracaine, lidocaine, benzocaine powders are excellent

—— Santino — Spain

The parcel I bought before was detained by the customs.I bought 300 kilograms of benzocaine to Canada without any customs problems from them. They made me receive the package in 17 days. They have such a great customs clearance team in Canada

—— Alex colley — Canada

There are no customs issues with the tetracaine hydrochloride and steroids powder I bought. They did it

—— Markcylano Alves — Brzail

I'm Online Chat Now

Anastrozole Arimidex Anti Estrogen Steroids ISO9001 CAS 120511-73-1

Anastrozole Arimidex Anti Estrogen Steroids ISO9001 CAS 120511-73-1

Large Image :  Anastrozole Arimidex Anti Estrogen Steroids ISO9001 CAS 120511-73-1

Product Details:
Place of Origin: China (whatsapp+8618971485175)
Brand Name: VKD
Certification: ISO9001,SGS,GMP
Model Number: 120511-73-1
Payment & Shipping Terms:
Minimum Order Quantity: 10g
Packaging Details: Aluminum foil bag + carton
Delivery Time: 1-2 work days
Payment Terms: Western Union, MoneyGram, T/T,bitcoins
Supply Ability: 100kg/month

Anastrozole Arimidex Anti Estrogen Steroids ISO9001 CAS 120511-73-1

High Light:

Anastrozole Arimidex Anti Estrogen Steroids


ISO9001 Anti Estrogen Steroids


CAS 120511-73-1

Detailed Product Description
Other Name: Arimidex MF: C17H19N5
MW: 293.37 Melting Point: 81-84°C
Storage Temp: Store At Refrigerator Appearance: White Crystalline Powder
High Light:

anti estrogen supplements


anti estrogen drugs




Powerful Anti-Estrogen Pharmaceutical Grade Anastrozole / Arimidex Raw Powder





Anastrozole is also called Arimidex, it can be referred to as an aromatase inhibitor which helps


prevent estrogen production in females. Research has shown that the estrogen hormone is


responsible for the creation of breast cancer tumors in women. Arimidex is the drug administered


to intercept the enzyme aromatase, which is a substance that assists the body tissues in


producing estrogen. Arimidex is a popular drug in the battle against breast cancer. It is by and


large, a hormonal treatment which can prevent the recurrence of breast cancer.



Arimidex is known to have diminished estrogen way too much in some patients. This is why blood


tests or salivary tests are recommended after a week of usage to determine whether the dosage


is appropriate.



Arimidex tends to work quite differently than the traditional anti-estrogens. Anti-estrogens like


Clomid or Nolvadex tend to intercept estrogen receptors in certain tissues while activating them


in others. Meanwhile, Arimidex directly intercepts the enzyme aromatase. When a patient has


been recommended the use of Arimidex, Clomid use along with is unnecessary. Doing so may


have some benefits.



Arimidex is generally used for all stages and forms of breast cancer which are classified to be


estrogen receptor positive. In case the patient has estrogen receptor negative or triple negative


cancer, the usage of Arimidex is unlikely to help.



Lab Test Result:



Test Items








White crystalline powder




Total Impurity






Total Unspecified Impurity


max. 0.2%




Individual unspecified impurlty


max. 0.1%




Related compound B


max. 0.2%




Related compound C


max. 0.2%




Related compound D


max. 0.1%




Related compound E


max. 0.1%




Limit of cyclohexane


max. 0.08%




Limit of ethylacetate


max. 0.1%




Melting point








max. 0.3%




Residue on ignition


max. 0.1%




Heavy Metals






Assay (HPLC)








It complies to USP32 Standard




An aromatase inhibitor. Used as an antineoplastic raw materials.

Potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 aromatase


enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast


cancer cell growth factors. Treatment of breast cancer, especially for those with hormone relapse


after adjuvant therapy after menopause for women with advanced breast cancer.



The drug is appropriately used when using substantial amounts of aromatizing steroids, or when


one is prone to gynecomastia and using moderate amounts of such steroids. Arimidex does not


have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen


blockade, much moreso than Cytadren. It is possible to reduce estrogen too much with Arimidex,


and for this reason blood tests, or less preferably salivary tests, should be taken after the first


week of use to determine if the dosing is correct.





Dosages of arimidex will vary from person to person. This is why blood work is essential to


finding the perfect balance. One should start out at half a mg every other day and adjust as


needed for the cycle. Some AAS users will not use an AI at first but they will have it on hand just in


case. This isn't always a good idea, as once you start noticing gyno or excessive water weight it


could be too late to reverse. Since AAS will continue building in the body and aromatize, taking


arimidex at this point would be like trying to stop a car already in motion.


General dosage for men: 0.5 mg per day or every other day



Anastrozole VS Letrozole


Aromatase inhibition is the gold standard for treatment of early and advanced breast cancer in


postmenopausal women suffering from an estrogen receptor-positive disease. The currently


established group of anti-aromatase compounds comprises two reversible aromatase inhibitors


(anastrozole and letrozole) and on the other hand, the irreversible aromatase inactivator


exemestane. Although exemestane is the only widely used aromatase inactivator at this stage,


physicians very often have to choose between either anastrozole or letrozole in general practice.


These third-generation aromatase inhibitors Letrozole and Anastrozole, have recently


demonstrated superior efficacy compared with tamoxifen as initial therapy for early breast cancer


improving disease-free survival. However, although anastrozole and letrozole belong to the same


pharmacological class of agents (triazoles), an increasing body of evidence suggests that these


aromatase inhibitors are not equipotent when given in the clinically established doses. Preclinical


and clinical evidence indicates distinct pharmacological profiles. Thus, this review focuses on the


differences between the non-steroidal aromatase inhibitors allowing physicians to choose


between these compounds based on scientific evidence. Although we are waiting for the


important results of a still ongoing head-to-head comparison in patients with early breast cancer


at high risk for relapse, clinicians have to make their choices today. On the basis of available


evidence summarised here and until FACE-data become available, letrozole seems to be the


best choice for the majority of breast cancer patients whenever a non-steroidal aromatase


inhibitor has to be chosen in a clinical setting.



Pharmaceutical Grade Anabolic Anti Estrogen Steroids Anastrozole Arimidex CAS 120511-73-1




Anti-Estrogen Series


Tamoxifen Citrate (Nolvadex)


Dutasteride (Avodart)


Clomifene Citrate (Clomid)


Finasteride (Proscar)


Letrozole (Femara)


Formestane (Lentaron)


Toremifene Citrate (Fareston)


Cabergoline (Caber)


Exemestane (Aromasin)


Raloxifene Hydrochloride


Anastrozole (Arimidex)






Contact: Allen



Contact Details
RawsGear Manufacturer

Contact Person: Cameron

Tel: +8618186204104

Send your inquiry directly to us (0 / 3000)